Antibe Therapeutics

Antibe Therapeutics Inc.
Publicly traded corporation
Traded as TSX-V: ATE
OTCQX: ATBPF
Industry Pharmaceuticals
Headquarters Toronto, Canada
Key people
Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Science Officer
Website www.antibethera.com

Antibe Therapeutics is a Toronto-based pharmaceutical company that develops inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. In 2015, Antibe acquired Citagenix, a developer and distributor involved in regenerative medicine.[2]

Products

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[3] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[4] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to rheumatoid arthritis and other diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[5]

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[6] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[7] In mid-January 2015, the company announced that clinical trials for its first drug were being suspended due to safety concerns; clinical trials were restarted in March 2015.[8]

Antibe's products have not yet been approved by the US Food and Drug Administration.

People

Antibe's science advisory board:[9]

Antibe’s board of directors:[11]

References

External links

This article is issued from Wikipedia - version of the 10/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.